Evidence map›Paper›PMID 35243772›Full record

ArticleJournal of applied clinical medical physics2023

Cardiac metabolic changes on

Sara J Zakem, Bernard Jones, Richard Castillo, Edward Castillo, Moyed Miften, Karyn A Goodman, Tracey Schefter, Jeffrey Olsen, Yevgeniy Vinogradskiy

Open access · goldAbstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Cardiac metabolic changes onJournal of applied clinical medical physics · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Sara J ZakemDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Bernard JonesDepartment of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Richard CastilloDepartment of Radiation Oncology, Emory University, Atlanta, Georgia, USA.
Edward CastilloDepartment of Radiation Oncology, Beaumont Health, Royal Oak, Michigan, USA.
Moyed MiftenDepartment of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Karyn A GoodmanDepartment of Radiation Oncology, Mount Sinai, New York, New York, USA.
Tracey SchefterDepartment of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Jeffrey OlsenDepartment of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Yevgeniy VinogradskiyDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
University of Colorado Denver · USBeaumont Health · USEmory University · USMount Sinai Hospital · USThomas Jefferson University · USUniversity of Washington · US

Funding

Development of a Novel Lung Function Imaging Modality for comprehensive management of lung cancerR01CA236857 · NCI · UNIVERSITY OF COLORADO DENVER · PI CASTILLO, EDWARD, CASTILLO, RICHARD · 2020 to 2025
$2.4M
NCI NIH HHS R01 CA236857
6 · The paper itself

Abstract

purposeHeart doses have been shown to be predictive of cardiac toxicity and overall survival (OS) for esophageal cancer patients. There is potential for functional imaging to provide valuable cardiac information. The purpose of this study was to evaluate the cardiac metabolic dose-response using

methodsFifty-one patients with esophageal cancer treated with radiation who underwent pre- and post-treatment FDG-PET scans were retrospectively evaluated. Pre- and post-treatment PET-scans were rigidly registered to the planning CT for each patient. Pre-treatment to post-treatment absolute mean SUV (SUVmean) changes in the heart were calculated to assess dose-response. A dose-response curve was generated by binning each voxel in the heart into 10 Gy dose-bins and analyzing the SUVmean changes in each dose-bin. Multivariate cox proportional hazard models were used to assess whether pre-to-post treatment cardiac SUVmean changes predicted for OS.

resultsThe cardiac dose-response curve demonstrated a trend of increasing cardiac SUV changes as a function of dose with an average increase of 0.044 SUV for every 10 Gy dose bin. In multivariate analysis, disease stage and SUVmean change in the heart were predictive (p < 0.05) for OS.

conclusionsChanges in pre- to post-treatment cardiac SUV were predictive of OS with patients having a higher pre- to post-treatment cardiac SUV change surviving longer.

Indexed as

Esophageal NeoplasmsFluorodeoxyglucose F18HeartHumansPositron-Emission TomographyRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticalscanceresophagealfunctional imagingheart dosePETradiation

Identifiers

PMID35243772
PMCPMC10476995
OpenAlexW4214856566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.